Alison Moskowitz
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Alison Moskowitz as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 15:23 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT05010005 · A Study of Ruxolitinib and Duvelisib in People With LymphomaMemorial Sloan Kettering Cancer Center · active not recruiting · T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia · principal investigator
- Ph2NCT04960618 · Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary SyndromeMemorial Sloan Kettering Cancer Center · active not recruiting · Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome · principal investigator
- Ph2NCT03728972 · Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal TypeMemorial Sloan Kettering Cancer Center · active not recruiting · NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis) · principal investigator
- Ph2NCT03618550 · Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · recruiting · Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma · principal investigator
- Ph2NCT03587844 · Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome PatientsMemorial Sloan Kettering Cancer Center · active not recruiting · Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome · principal investigator
- Ph2NCT03179917 · Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · active not recruiting · Hodgkin Lymphoma · principal investigator
- Ph2NCT03179930 · Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory LymphomasMemorial Sloan Kettering Cancer Center · active not recruiting · Lymphoma, Relapsed, Refractory · principal investigator
- Ph1/Ph2NCT03033914 · A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)Memorial Sloan Kettering Cancer Center · active not recruiting · Hodgkin Lymphoma · principal investigator
- Ph2NCT02974647 · Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaMemorial Sloan Kettering Cancer Center · recruiting · Lymphoma · principal investigator
- Ph1/Ph2NCT02429375 · Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaMemorial Sloan Kettering Cancer Center · completed · Hodgkin Lymphoma · principal investigator
- N/ANCT02106611 · Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) SurvivorsMemorial Sloan Kettering Cancer Center · completed · Hodgkin Lymphoma Survivor · principal investigator
- Ph1NCT01902160 · Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaNational Cancer Institute (NCI) · completed · Recurrent Adult Hodgkin Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 15:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Center AdministrationP30CA008748 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ALEX MACDONALD · fiscal years 2011 to 2026Named on NCT01902160
- Early Clinical Trials of New Anti-Cancer Agents with Phase 1 EmphasisU01CA069856 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID R SPRIGGS · fiscal years 2011 to 2013Named on NCT01902160
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 15:23 UTC. The ranking covers the 200 most relevant of 94 PubMed records, and a shared surname and initials can bring in a namesake. All 94 on PubMed
- 3,031 citationsRCR 77.1
- 869 citationsRCR 36.6
- 737 citationsRCR 26.7
- 655 citationsRCR 24.7
- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.Lancet Oncol · 2018563 citationsRCR 19.4
- Two-Year Outcomes of Surgical Treatment of Moderate Ischemic Mitral Regurgitation.N Engl J Med · 2016390 citationsRCR 14.2
- Surgical ablation of atrial fibrillation during mitral-valve surgery.N Engl J Med · 2015388 citationsRCR 15.4
- Surgical treatment of moderate ischemic mitral regurgitation.N Engl J Med · 2014331 citationsRCR 10.4
- Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.N Engl J Med · 2016302 citationsRCR 11.9
- 260 citationsRCR 8.2